Kogenate Bayer Eiropas Savienība - horvātu - EMA (European Medicines Agency)

kogenate bayer

bayer ag  - octocog alfa - hemofilija a - antihemorrhagics - liječenje i profilaksu krvarenja u bolesnika s hemofilijom a (nedostatak prirođenih faktora viii). ovaj lijek ne sadrži faktor Виллебранда i stoga nije navedeno u bolest pozadina Виллебранда .

Fasenra Eiropas Savienība - horvātu - EMA (European Medicines Agency)

fasenra

astrazeneca ab - benralizumab - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - fasenra navodi kao dodatne terapije kod odraslih pacijenata s teškim eozinofilni astmom, adekvatno kontrolirati, bez obzira na visoke doze udahnuti glukokortikoidi plus dugog djelovanja β-адреномиметиков.

FORTICOAT NL Horvātija - horvātu - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

forticoat nl

kk biovit d.o.o., zagreb, hrvatska - sorbinska, mravlja, octena, mliječna i propionska kiselina, amonijev formijat, l-askorbinska kiselina, limunska kiselina, mono- i digliceridi masnih kiselina i prirodni ekstrakt kvasaca - koncentrirana otopina za primjenu u vodi za piće - peradi i svinja

Abecma Eiropas Savienība - horvātu - EMA (European Medicines Agency)

abecma

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastična sredstva - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Rybrevant Eiropas Savienība - horvātu - EMA (European Medicines Agency)

rybrevant

janssen-cilag international n.v.    - amivantamab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Carvykti Eiropas Savienība - horvātu - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - multipli mijelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

ISOPRINOSINE 1000 mg/1 kesica prašak za oralni rastvor Bosnija un Hercegovina - horvātu - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

isoprinosine 1000 mg/1 kesica prašak za oralni rastvor

ewopharma d.o.o. sarajevo - inozin acedoben dimepranol - prašak za oralni rastvor - 1000 mg/1 kesica - jedna kesica sa praškom za oralni rastvor sadrži 1000 mg inozin acedoben dimepranola

ISOPRINOSINE 50 mg/1 mL sirup Bosnija un Hercegovina - horvātu - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

isoprinosine 50 mg/1 ml sirup

ewopharma d.o.o. sarajevo - inozin acedoben dimepranol - sirup - 50 mg/1 ml - 1 ml sirupa sadrži 50 mg inozin acedoben dimepranola (jedna kašika za doziranje od 5 ml sadrži 250 mg inozin acedoben dimepranola)